Crizotinib-induced fatal fulminant liver failure

Robin M J M van Geel; Jeroen J M A Hendrikx; Jelmer E. Vahl; Monique E. van Leerdam; Daan van den Broek; Alwin D R Huitema; Jos H. Beijnen; Jan H M Schellens; Sjaak A. Burgers

doi:10.1016/j.lungcan.2015.12.010

Crizotinib-induced fatal fulminant liver failure

Robin M J M van Geel^*, Jeroen J M A Hendrikx, Jelmer E. Vahl, Monique E. van Leerdam, Daan van den Broek, Alwin D R Huitema, Jos H. Beijnen, Jan H M Schellens, Sjaak A. Burgers

^*Corresponding author for this work

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.

Original language	English
Pages (from-to)	17-19
Number of pages	3
Journal	Lung Cancer
Volume	93
DOIs	https://doi.org/10.1016/j.lungcan.2015.12.010
Publication status	Published - 1 Mar 2016

Keywords

Crizotinib
Fulminant liver failure
Hepatotoxicity
Non-small cell lung cancer

Access to Document

10.1016/j.lungcan.2015.12.010

crizotinibFinal published version, 218 KBLicence: Taverne

Cite this

@article{7ce62a8d52e14fdeb1a6d8329a8df8ed,

title = "Crizotinib-induced fatal fulminant liver failure",

abstract = "Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.",

keywords = "Crizotinib, Fulminant liver failure, Hepatotoxicity, Non-small cell lung cancer",

author = "{van Geel}, {Robin M J M} and Hendrikx, {Jeroen J M A} and Vahl, {Jelmer E.} and {van Leerdam}, {Monique E.} and {van den Broek}, Daan and Huitema, {Alwin D R} and Beijnen, {Jos H.} and Schellens, {Jan H M} and Burgers, {Sjaak A.}",

year = "2016",

month = mar,

day = "1",

doi = "10.1016/j.lungcan.2015.12.010",

language = "English",

volume = "93",

pages = "17--19",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd.",

}

TY - JOUR

T1 - Crizotinib-induced fatal fulminant liver failure

AU - van Geel, Robin M J M

AU - Hendrikx, Jeroen J M A

AU - Vahl, Jelmer E.

AU - van Leerdam, Monique E.

AU - van den Broek, Daan

AU - Huitema, Alwin D R

AU - Beijnen, Jos H.

AU - Schellens, Jan H M

AU - Burgers, Sjaak A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.

AB - Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.

KW - Crizotinib

KW - Fulminant liver failure

KW - Hepatotoxicity

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84959423187&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.12.010

DO - 10.1016/j.lungcan.2015.12.010

M3 - Article

AN - SCOPUS:84959423187

SN - 0169-5002

VL - 93

SP - 17

EP - 19

JO - Lung Cancer

JF - Lung Cancer

ER -

Crizotinib-induced fatal fulminant liver failure

Abstract

Keywords

Access to Document

Fingerprint

Cite this